Deric Park to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Deric Park has written about Xenograft Model Antitumor Assays.
Connection Strength
1.120
-
LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. Cancer Lett. 2018 02 28; 415:217-226.
Score: 0.516
-
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. JCI Insight. 2019 10 17; 4(20).
Score: 0.147
-
Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma. Neuro Oncol. 2018 05 18; 20(6):799-809.
Score: 0.133
-
Cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF-1a in human glioma stem cells. Oncotarget. 2017 Jun 20; 8(25):40233-40245.
Score: 0.125
-
Isolation and Propagation of Glioma Stem Cells from Acutely Resected Tumors. Methods Mol Biol. 2016; 1516:361-369.
Score: 0.113
-
Combination of PARP inhibitor and temozolomide to suppress chordoma progression. J Mol Med (Berl). 2019 08; 97(8):1183-1193.
Score: 0.036
-
Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Rep. 2017 01; 18(1):150-168.
Score: 0.030
-
The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma. J Neurosurg. 2010 Aug; 113(2):225-33.
Score: 0.019